FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

A Waukesha County deputy is battling a "rare, aggressive cancer." Steve Lyles has been with the department for nearly 20 ...

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

In a remarkable journey of resilience, 12-year-old dancer Lauren Torres has defied the odds after undergoing a life-saving ...

Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

Despite guidelines addressing overdetection, no significant declines are seen; emphasis on active surveillance approaches is ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...